About Glycostem Therapeutics

Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.   

High log-scale expansion of functional human Natural Killer cells from Umbilical Cord Blood.

Glycostem Therapeutics' researchers published in 2010 and 2011 groundbreaking results on the ex-vivo expansion of functional human natural killer cells from Umbilical Cord Blood (UCB) for adoptive cancer immunotherapy.

UCB holds great promise as unique and abundantly available source material for future cellular therapies, but so far cannot be exploited at large for that purpose, due technological limitations.
 
In order to broaden the application to other therapeutics areas there is a clear need for new technologies to expand and differentiate Haematopoietic Stem Cells from UCB.

The development of such technology is prime expertise of Glycostem Therapeutics, see:

Spanholtz et al. “High log-scale expansion of functional human natural killer cells from umbilical cord blood cells for adoptive cancer immunotherapy"

www.plosone.org
February 2010 Vol. 5 Issue 2 e9221

Spanholtz et al. "Clinical-Grade Generation of Active NK Cells from Cord
Blood Hematopoietic Progenitor Cells for
Immunotherapy Using a Closed-System Culture Process "

www.plosone.org
June 2011 Vol. 6 Issue 6 e20740